Ignyta, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2
Founded: San Diego California United States (2011)
Status: Acquired by Roche (2018)

Organization Overview

First Clinical Trial
2011
NCT01226485
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Chief Medical Officer, Ignyta, Inc. | Ignyta, Inc.